May 2009
Worldwide Biotech;May2009, Vol. 21 Issue 5, p2
Trade Publication
This article reports on the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a selective inhibitor of monoamine oxidase B, conducted by Evotec AG of Hamburg, Germany. The study found that EVT 302 failed to demonstrate any significant improvement in the quit rate compared with placebo. It also showed that the combination of EVT 302 with a nicotine replacement patch failed to demonstrate any significant benefit over nicotine replacement therapy (NRT) alone.


Related Articles

  • Evotec Options Narrow on Smoking Trial Miss. Sheridan, Cormac // BioWorld International;4/22/2009, Vol. 14 Issue 16, p1 

    The article reports that the plan of Evotec AG for a partnership is in trouble after its smoking cessation drug EVT 302 did not present efficacy in a Phase II proof-of-concept trial. According to results of the trial, the selective monoamine oxidase B (MAO B)inhibitor did not demonstrate...

  • Roche Bets up to $830M On Evotec's MAO-B for AD. Moran, Nuala // BioWorld International;9/7/2011, Vol. 16 Issue 36, p1 

    The article discusses the out-licensing of the monoamine oxidase type B (MAO-B) product for Alzheimer's disease by Evotec AG to Roche AG amounting to 830 million dollars. Evotec will receive 10 million dollars at the start, 170 million dollars in short-term clinical milestones and the balance in...

  • Roche Bets up to $830M On Evotec's MAO-B for AD. Moran, Nuala // BioWorld Today;9/7/2011, Vol. 22 Issue 173, p1 

    The article reports that Roche AG will assume all development and commercialization costs for Evotec AG's lead monoamine oxidase type B (MAO-B) product for Alzheimer's disease. The deal will call for Evotec AG to start a large Phase IIb trial in 2012 powered to show that EVT 302, an orally...

  • Evotec's MAO-B Inhibitor Fails in Phase II Smoking Cessation Trial.  // BioWorld Today;4/15/2009, Vol. 20 Issue 71, p2 

    The article reports on the failure of a phase II proof-of-concept study of smoking cessation drug EVT 302 from Evotec AG to show statistically significant improvement in the quit rate of smokers. The company is planning to reassess the future of the drug following further analysis. EVT 302, a...

  • A Placebo-Controlled Trial of Pioglitazone in Subjects with NonAlcoholic Steatohepatitis. Robinson, Malcolm // Internal Medicine Alert;2/28/2007, Vol. 29 Issue 4, p27 

    Although often unrecognized, nonalcoholic steatohepatitis (NASH) is an increasingly common chronic liver disease that can progress to cirrhosis and hepatoma. Typical features associated with NASH include obesity, fatty liver disease, and type 2 diabetes mellitus. Proposed treatments have...

  • Effects of pro-cholinergic treatment in patients suffering from spatial neglect. Lucas, N.; Saj, A.; Schwartz, S.; Ptak, R.; Thomas, C.; Conne, P.; Leroy, R.; Pavin, S.; Diserens, K.; Vuilleumier, Patrik // Frontiers in Human Neuroscience;Sep2013, Vol. 7, p1 

    Spatial neglect is a neurological condition characterized by a breakdown of spatial cognition contralateral to hemispheric damage. Deficits in spatial attention toward the contralesional side are considered to be central to this syndrome. Brain lesions typically involve right fronto-parietal...

  • Effects of acute nicotine on auditory change-related cortical responses. Otsuru, Naofumi; Tsuruhara, Aki; Motomura, Eishi; Tanii, Hisashi; Nishihara, Makoto; Inui, Koji; Kakigi, Ryusuke // Psychopharmacology;Nov2012, Vol. 224 Issue 2, p327 

    Rationale and objective: Nicotine is known to have enhancing effects on some aspects of attention and cognition. The purpose of the present study was to elucidate the effects of nicotine on pre-attentive change-related cortical activity. Methods: Change-related cortical activity in response to...

  • Drug Treatment of Social Anxiety Disorder. Mayers, Andrew G.; Baldwin, David // Current Medical Literature: Psychiatry;2003, Vol. 14 Issue 3, p55 

    Presents a study that examined the pharmacological treatment of social anxiety disorder. Side effects of monoamine oxidase inhibitors; Comparison between the effectiveness of moclobemide and placebo; Details of tricyclic antidepressants for treating social phobia.

  • The Future of Depression Psychopharmacology. Belmaker, Robert H. // CNS Spectrums: The International Journal of Neuropsychiatric Med;Aug2008, Vol. 13 Issue 8, p682 

    Along with the development of selective sertonin reuptake inhibitors there has been a tremendous widening of the definition of depression and an impressive decrease in the placebo-drug difference in controlled studies. In the early 1960s, about one third of depressed patients improved with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics